NOVARTIS
๐จ๐ญSwitzerland
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 336
- Registration Number
- NCT00219102
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
๐บ๐ฆInvestigative Site, Kiev, Ukraine
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 355
- Registration Number
- NCT00219167
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1797
- Registration Number
- NCT00219180
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 504
- Registration Number
- NCT00219076
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 180
- Registration Number
- NCT00219050
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
๐ช๐ธInvestigative Site, Madrid, Spain
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2775
- Registration Number
- NCT00219024
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (โฅ 18 Years) With Stable Heart Failure
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 280
- Registration Number
- NCT00219011
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 493
- Registration Number
- NCT00219115
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Registration Number
- NCT00219219
- Locations
- ๐ฎ๐น
Bologna, Bologna, Italy
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 844
- Registration Number
- NCT00219063
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath